Genmab's US partner, Janssen, has received a positive opinion from the CHMP, a committee that is part of the European Medicines Agency, and a recommendation that its candidate receives conditional marketing authorization in Europe for the treatment of non-small cell lung cancer. The dug is called amivantamab, with the commercial name Rybrevant.
CEO of Genmab Jan van de Winkel is especially pleased with this development, as this is the first time the CHMP has given a positive opinion on a product developed using Genmab's Duobody technology.
More from MedWatch
Experiences from Danish climate partnerships are among the tools that can be leveraged when Novo Nordisk CEO Lars Fruergaard begins stepping up efforts in the life science sector’s central organs in Brussels. ”I’ve been fired up by the intimacy and shared vision we could see in Denmark,” he tells MedWatch.